News

March 13, 2010

03:43

Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) (PR Newswire)

Orexigen® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc. , a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release /bupropion HCL SR) as well as development of future formulations of Orexigen products. The financial terms of the deal were not disclosed.

Source: PATHEON INCORPORATED

March 12, 2010

17:53

Canada corporate earnings schedule - Mar 1-19

Source: ANGIOTECH PHARMACEUTICALS INC

17:53

Resverlogix Activates First Site for ASSURE 1 Clinical Trial (CNW Group)

Source: RESVERLOGIX CORP

17:53

Orexigen signs Patheon to manufacture weight drugs (at Reuters)

Source: PATHEON INCORPORATED

17:53

Medicure Announces Further Agreement With Secured Lender (Marketwire)

Source: MEDICURE INC

17:53

Timbercreek Mortgage Investment Corp. announces December 31, 2009 results of operations (CNW Group)

Source: TM BIOSCIENCE CORP

17:53

Pyng Medical Receives European CE Mark for FASTx(TM) (Marketwire)

Source: PYNG MEDICAL CORP.

17:53

Sonomax security holders approve Arrangement with Benvest New Look Income Fund (CNW Group)

Source: SONOMAX HEARING HEALTHCARE INC

16:15

Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) (PR Newswire)

OrexigenÂ® Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc. , a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of ContraveÂ® (naltrexone HCL sustained release /bupropion HCL SR) as well as development of future formulations of Orexigen products. Â The financial terms of the deal were not disclosed.

Source: PATHEON INCORPORATED

13:52

Paladin Reports Fourteenth Consecutive Year of Record Revenues (CCNMatthews)

Source: PALADIN LABS INC

13:52

BTG and Paladin Complete Agreement for Digifab for the Treatment of Digoxin Toxicity (CCNMatthews)

Source: PALADIN LABS INC

13:52

Paladin to Present at the RBC Capital Markets Healthcare Conference in New York City (CCNMatthews)

Source: PALADIN LABS INC

11:44

Lifebank Becomes the First and Only Canadian Cord Blood Bank To Achieve Industry-Leading FACT Accreditation (CCNMatthews)

Source: LIFEBANK CORP.

09:51

Labopharm Reports Results for Fourth Quarter and Fiscal Year 2009 (CNW Group)

Source: LABOPHARM INC

08:30

Data for SemBioSys' APO AI(Milano) to be presented at the American College of Cardiology's 59th Annual Scientific Session (CNW Group)

Source: SEMBIOSYS GENETICS INC

08:30

Spectral announces presentations at the 8th Annual World Congress on Trauma, Shock, Inflammation and Sepsis focusing on the role of endotoxin (CNW Group)

Source: SPECTRAL DIAGNOSTICS INC

07:16

Data for SemBioSys' APO AI(Milano) to be presented at the American College of Cardiology's 59th Annual Scientific Session (CNW Group)

Source: SEMBIOSYS GENETICS INC

07:16

Timbercreek Mortgage Investment Corporation Announces Closing of Offering of Class A Shares (CNW Group)

Source: TM BIOSCIENCE CORP

07:15

Spectral announces presentations at the 8th Annual World Congress on Trauma, Shock, Inflammation and Sepsis focusing on the role of endotoxin (CNW Group)

Source: SPECTRAL DIAGNOSTICS INC

04:07

Transition Therapeutics to Present at Upcoming Conferences (GlobeNewswire)

Source: TRANSITION THERAPEUTICS INC